<DOC>
	<DOCNO>NCT02964091</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy , safety tolerability medication , ledipasvir/sofosbuvir ( LDV/SOF ) , use treat individual chronic hepatitis C virus ( HCV ) Rwandan adult . A sub-cohort participant limited laboratory monitoring determine minimum laboratory test necessary .</brief_summary>
	<brief_title>Simplifying Hepatitis C Antiviral Therapy Rwanda Elsewhere Developing World</brief_title>
	<detailed_description>This open-label single arm study evaluate antiviral efficacy , safety tolerability ledipasvir/sofosbuvir fix dose combination administer 12 week HCV treatment-naive treatment-experienced participant chronic genotype 1 4 HCV infection . Approximately 240 participant enrol treated sofosbuvir ( SOF ) 400 mg/LDV 90 mg fix dose combination ( FDC ) one tablet daily 12 week SHARED 1 study . Sixty additional participant enrol SHARED 2 sub-cohort laboratory monitoring blind study clinician .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>patient willing able provide write informed consent age ≥ 18 year HCV RNA ≥ 103 IU/mL HCV genotype 1 4 screen ultrasound exclude hepatocellular carcinoma ( HCC ) acceptable laboratory value ( hemoglobin ≥8.0 g/dL , platelet count ≥40,000/mm3 ; AST , ALT , alkaline phosphatase ≤10 × ULN ; creatinine clearance ≥30 mL/min ) general good health ability comply study procedure HIVinfected patient must complete least 6 month approve HIV antiretroviral therapy ( ART ) per Rwanda National Guidelines 2013 , take least 2 week prior screen ART compatible SOF/LDV ( efavirenz , rilpivirine , raltegravir , dolutegravir , emtricitabine , lamivudine , zidovudine , tenofovir ) , screen HIV RNA &lt; 200 copies/mL , screen CD4 Tcell count ≥100 cells/µL current history clinical hepatic decompensation ( i.e. , ascites , encephalopathy variceal hemorrhage ) active tuberculosis clinicallysignificant illness ( except HCV and/or HIV ) major medical disorder active Hepatitis B infection difficulty blood collection and/or poor venous access purpose phlebotomy IFNcontaining regimen within 8 week prior screen prior exposure HCVspecific directacting antiviral agent ( NS3/4A protease inhibitor SOF ) , current pregnancy breastfeeding , active drug alcohol use dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>sofosbuvir/ledipasvir</keyword>
	<keyword>Efficacy</keyword>
</DOC>